VIRA 38 to Be Provided to Southeast Asian Nations to Combat Bird Flu (H5N1)
HONG KONG -- PRB Pharmaceuticals and Lees Pharmaceuticals announced that they are working with government and hospital officials in Southeast Asia to provide VIRA 38 for the treatment and prevention of bird flu (H5N1). VIRA 38 is on the market in Hong Kong and the will be available in China and Taiwan soon.
VIRA 38, a composition of plant extracts, first gained notoriety during the Taiwan SARS outbreak of 2003 when it was used by the Taiwan presidential staff and doctors at Sungshan Hospital (SARS management facility) and again in the spring of 2004 when it was discovered that compounds in VIRA 38 block bird flu virus (H5N1) infections.
The World Health Organization has urged our industry to step up efforts to address the bird flu situation. To meet this challenge, we are donating VIRA 38 to medical staff and select high risk groups in bird flu-afflicted areas, said Dr. Charles Hensley, chairman and CEO of PRB Pharmaceuticals.
VIRA 38 will be used initially to protect high-risk groups such as hospital medical staff and rural farming households, said Dr. Benjamin Li, CEO of Lees Pharmaceuticals. It is of critical importance to protect the population at large. VIRA 38 is currently being used as a preventive measure by workers in live poultry markets in Hong Kong, the source of the original outbreak of bird flu in humans.
Our concern with the situation in Southeast Asia and Vietnam in particular is that as more human bird flu cases occur, the chances become greater the virus will ignite a global pandemic that could kill up to 100 million people worldwide, added Hensley. This is a deadly game of Russian Roulette.
About VIRA 38
VIRA 38, PRB Pharmaceuticals over-the-counter broad spectrum anti-viral medication is known for its effectiveness in treating and preventing influenza. VIRA 38 has recently been shown to contain compounds that inhibit the bird flu (H5N1) virus. Researchers at the Chinese University of Hong Kong have previously discovered these same compounds to be effective against a variety of pathogens including SARS CoV, the virus responsible for causing severe acute respiratory syndrome.
Source: PRB Pharmaceuticals
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.
From Shortages to Security: How Reusable Health Care Textiles Can Transform Infection Prevention
March 7th 2025Reusable health care textiles enhance infection prevention, reduce waste, and strengthen supply chains. Hygienically clean textiles offer a sustainable, cost-effective alternative to disposable PPE, ensuring patient safety and environmental responsibility.
